Overview: Vitamin D Ultrasensitive Panel
Introduction: The Vitamin D Ultrasensitive Panel is a diagnostic tool designed for vitamin D deficiency screening using serum samples. In India, severe vitamin D deficiency (<10 ng/mL) is common (~30-50 percent in certain groups), contributing to secondary hyperparathyroidism, bone loss, and increased fracture risk, especially in elderly, veiled women, and urban indoor workers. High morbidity from under-testing leading to delayed high-dose supplementation, causing persistent musculoskeletal pain or falls. Per endocrinology practices aligned with ICMR, Endocrine Society of India, and National Nutrition Monitoring Bureau guidelines, the test employs immunoassay for 25-OH vitamin D, calcium, and PTH over 1â€"2 days with high accuracy, valuable for ultrasensitive detection in borderline cases and monitoring PTH response. This diagnostic falls under nutritional screening and targets patients with chronic bone pain, elderly, or high-risk groups, addressing accurate detection to guide cholecalciferol dosing. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise vitamin D/PTH profiling and reducing skeletal complications. Its serum-based approach ensures reliable multi-parameter assessment.
Other Names: Vit D Ultra Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.
Historical Milestone: 25-OH vitamin D + PTH standard for deficiency workup; in India, expanding in geriatric care.
Purpose: The test assesses 3 parameters including 25-OH Vitamin D to guide vitamin D deficiency screening, detect low levels/PTH elevation, inform supplementation.
Test Parameters: 1. 25-OH Vitamin D, 2. Calcium, 3. PTH.
Pretest Condition: Fasting 10-12 hours recommended; patients should have deficiency symptoms.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on bone pain, sun exposure.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected deficiency including fractures, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Low 25-OH vitamin D + elevated PTH indicates secondary hyperparathyroidism, necessitating specialist input.
Specialist Consultation: Endocrinologists should be consulted for management.
Additional Supporting Tests: Alkaline phosphatase, bone densitometry for confirmation.
Test Limitations: Seasonal variation; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Nutrition Studies India 2023.
